Annual Drug Patent Expirations for LEXISCAN
Lexiscan is a drug marketed by Astellas and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for LEXISCAN.
This drug has fifty-three patent family members in twenty-six countries.
The generic ingredient in LEXISCAN is regadenoson. Two suppliers are listed for this compound. Additional details are available on the regadenoson profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
